{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:49:38Z","timestamp":1648993778313},"reference-count":18,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.vaccine.2008.09.001","type":"journal-article","created":{"date-parts":[[2008,9,19]],"date-time":"2008-09-19T08:57:07Z","timestamp":1221814627000},"page":"6293-6294","source":"Crossref","is-referenced-by-count":2,"title":["Cervical cancer vaccination: The real meaning of cross-protection and its impact on the prevention"],"prefix":"10.1016","volume":"26","author":[{"given":"Newton Sergio","family":"De Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5035","key":"10.1016\/j.vaccine.2008.09.001_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.1659743","article-title":"Viruses in human cancers","volume":"254","author":"Zur Hausen","year":"1991","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2008.09.001_bib2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide prospective","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2008.09.001_bib3","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2008.09.001_bib4","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2008.09.001_bib5","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"9447","key":"10.1016\/j.vaccine.2008.09.001_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2008.09.001_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.09.001_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Mu\u00f1oz","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2008.09.001_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/gyno.2000.5826","article-title":"The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States\u2014a 24-year population-based study","volume":"78","author":"Smith","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2008.09.001_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"issue":"9518","key":"10.1016\/j.vaccine.2008.09.001_bib11","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2008.09.001_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9580","key":"10.1016\/j.vaccine.2008.09.001_bib13","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2008.09.001_bib14","unstructured":"Gall SA, Teixeira J, Wheeler WM, Substancial impact on precancereous lesions and HPV infections through 5.5 years in women vaccinated with HPV-16\/18 L1 VLP AS04 candidate vaccine. Presented at the American Association for Cancer Research (AACR) annual meeting on April 14\u201318, 2007, Los Angeles, CA [abstract no. 4900]."},{"issue":"3","key":"10.1016\/j.vaccine.2008.09.001_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003495-200868030-00007","article-title":"Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix\u2122]","volume":"68","author":"Keam","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2008.09.001_bib16","first-page":"158","article-title":"Sustained immunogenicity and high efficacy against HPV-16\/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix\u2122 (GSK\u2019s HPV 16\/18 AS04 candidate vaccine)","volume":"109","author":"Harper","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.vaccine.2008.09.001_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajog.2007.08.055","article-title":"Reducing the burden of glandular carcinomas of the uterine cervix","volume":"197","author":"Herzog","year":"2007","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"10.1016\/j.vaccine.2008.09.001_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/14750708.5.3.313","article-title":"Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials","volume":"5","author":"Harper","year":"2008","journal-title":"Therapy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T10:41:20Z","timestamp":1588934480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08012255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":18,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0264410X08012255"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}